ORIGINAL ARTICLES
VOLUME: 20
ISSUE: 1
P: 19-27#19-27
March 2026
The Frequency and Clinical Findings of Human Bocavirus
in Hospitalized Children: A Tertiary Hospital Experience in
İstanbul
Journal of Pediatric Infection • 2026
DOI: 10.5578/ced.20260117
Received Date: 06.02.2025
Accepted Date: 27.05.2025
Publish Date: 17.03.2026
ABSTRACT
Objective
Human bocavirus (HBoV), the predominant viral contributor
to respiratory tract infections (RTIs) in children, remains a global health
challenge. This study aimed to delineate the frequency and clinical
manifestations of HBoV in pediatric patients admitted to a tertiary
healthcare hospital’s pediatric infectious diseases clinic in İstanbul,
thereby contributing to a broader understanding of its impact.
Material and Methods
A retrospective review of children under 18
years of age hospitalized for RTIs was conducted from June 2021 to
February 2023. The demographic, clinical, and laboratory data were
evaluated using descriptive statistics and comparative tests.
Results
: A total of 48 hospitalized children tested positive for HBoV. Median age was 18.5 months [interquartile range (QR): 9.0-30.0], and 58.3%
of the patients were male. Most patients (85.4%) had no chronic diseases and 66.7% were born via cesarean section. Autumn was the most
frequent admission season (64.6%). The predominant symptoms were
coughing (77.1%) and fever (75.0%). Respiratory distress was observed in
47.9% of the patients, and 75.0% required oxygen supplementation, primarily via masks (41.7%). Chest radiographs showed infiltration in 41.7%
of the cases. Inhaler use was reported in 62.5% of patients, whereas
antibiotics were initiated in 85.4% the of patients. Oseltamivir was administered only to patients with co-infection (20.0%, p= 0.043), and steroid
use was more frequent in this group (46.7% vs. 22.2%, p= 0.090). Among
all patients, 22.9% required intensive care unit admission. Co-infection
with at least one other respiratory virus, most commonly respiratory syncytial virus (20.8%), was observed in 62.5% of the cases. No significant
differences were found between the HBoV-only and HBoV-co-infected
groups in terms of demographic variables, symptoms, laboratory parameters, or hospitalization duration.
Conclusion
This study elucidated the pivotal role of HBoV in pediatric
RTIs. HBoV is associated with a high rate of coinfection with other respiratory viruses. This study contributes to a broader understanding of
HBoV infections and can guide clinicians in implementing appropriate
treatment strategies.
KEYWORDS
Human bocavirus (HBoV), pediatric respiratory tract infections (RTIs), co-infections, viral etiology
INTRODUCTION
Respiratory tract infections (RTIs) continue to pose
substantial health challenges among pediatric populations
globally given their contribution to morbidity and mortality
rates. Viruses are predominantly responsible for these
infections, with human bocavirus (HBoV) emerging as a critical
pathogen after its identification in 2005 (1). HBoV, a linear
single-stranded DNA virus belonging to the Parvoviridae
family, is typically associated with acute RTIs, particularly in
children below five years of age (2-4).
Several studies have investigated the role of HBoV in
pediatric RTIs and their frequency across diverse geographic
locations. A study conducted in Egypt identified HBoV as a
significant viral contributor to pediatric RTIs, as evidenced by
findings at Benha University Hospital (5). Correspondingly,
research in India has underscored the prevalence of HBoV in
children with acute RTIs (4). Italian research has outlined the
clinical and serological attributes of pediatric RTIs associated
with HBoV (2).
Observations indicate a variation in the frequency of
HBoV infections in pediatric patients depending on regional
factors. For instance, an investigation conducted in Singapore
revealed that the frequency of HBoV infection among 1024
hospitalized children was 8% (6). Similarly, Iranian research has
confirmed the presence of HBoV in 8% of 261 Iranian children
aged <5 years experiencing acute respiratory infections (7).
Nevertheless, the precise frequency of HBoV infections and
their contribution to the overall pediatric RTI burden remain
somewhat nebulous, warranting further comprehensive
research.
This study contributes to the growing body of knowledge
by examining the frequency and clinical manifestations of
HBoV in children hospitalized at the pediatric infectious
diseases clinic of a tertiary healthcare hospital in Istanbul.
A thorough understanding of the burden of HBoV in this
region will be instrumental in crafting suitable management
strategies and contribute to a more comprehensive global
understanding of HBoV in pediatric RTIs
MATERIALS AND METHODS
This study was retrospectively conducted by scanning the
files of children under 18 years of age who were hospitalized
for upper and lower RTIs in the pediatric infectious diseases
clinic between June 2021 and February 2023. Demographic,
clinical, and laboratory data were evaluated. This study was
approved by the local ethics committee of Prof. Dr. Cemil
Taşçıoğlu City Hospital (13.01.2025/05).
Nasopharyngeal swab samples were collected from viral
transport media (Copan Diagnostics, Italy). RTI pathogens
were detected using the Bio-Speedy Respiratory Tract realtime polymerase chain reaction (PCR) MX -24S multiplex PCR
Panel (Bioeksen, Türkiye).
Inclusion criterion was children under 18 years of age
hospitalized for RTIs with a confirmed HBoV detection
via multiplex PCR. Exclusion criteria included incomplete
clinical records, hospitalization for non-respiratory causes,
or unrelated immunosuppressive conditions. From an initial
pool of 61 eligible patients, 13 were excluded, resulting in a
final cohort of 48 patients.
Statistical analysis
The mean, standard deviation (SD), median lowest, highest,
frequency, and ratio values were used in the descriptive
statistics of the data. The distribution of variables was tested
using the Kolmogorov-Smirnov test. For non-normally
distributed variables, medians and interquartile ranges (IQR)
were calculated and analyzed using the Mann-Whitney U
test. The chi-square test was used to analyze independent
qualitative data, and the Fischer test was used when the chisquare test conditions were not met. SPSS 28.0 program was
used for the analysis.
RESULTS
Our study population consisted of 48 children with HBoV
infection, ranging in age from 1.5 to 102.0 months, with a
median age of 18.5 months (IQR: 9.0-30.0). Sex distribution
showed a slight male predominance, with 41.7% female
patients and 58.3% male patients.
Most of the children (85.4%) had no chronic diseases.
However, among those with preexisting chronic conditions
(14.6%), the most common was Down syndrome (6.3%).
Hospital admission period ranged from June to December,
with November accounting for the highest percentage of
admissions (52.1%). When categorized by season, most
admissions occurred in the autumn (64.6%). Regarding
birth-related variables, most children were born via cesarean
section (66.7%), in the term period (75.0%), and with an
average birth weight for gestational age (85.4%). The results
of the evaluation of the demographic, clinical, and laboratory
data are presented in Table 1.
The most common symptoms observed in the children
were cough (77.1%) and fever (75.0%). Respiratory distress
was observed in 47.9% of the patients, and gastrointestinal
symptoms such as diarrhea and vomiting were reported in
18.8% of the patients. Upon physical examination, 89.6% of
the children showed pathological findings, with the most
common being a coarse breathing voice (75.0%). Chest
radiograms showed normal findings in 35.4% of the patients,
whereas infiltration was detected in 41.7% of the cases.
Regarding treatment, inhaler usage was reported in 62.5% of
the patients. Most children (85.4%) received antibiotics until
the virus was detected, and ampicillin-sulbactam was the most
commonly used antibiotic (45.8%). A significant proportion of
the patients (75.0%) required oxygen supplementation, with
the most common method being via mask (41.7%). Mean
number of febrile days was 2.85 (± 2.19 SD), with a median
of 3.0 days. Mean hospital stay was 6.65 days (± 2.38) days.
Among these patients, 22.9% required admission to the
intensive care unit. Data related to the symptoms, physical
examination findings, chest X-ray findings, and treatment
approaches of the study population are presented in Table 2.
Of the patients, 41.7% had one additional virus detected,
16.7% had two, and 4.2% had three. A sizable proportion
(37.5%) of the patients showed no viruses other than HBoV.
Regarding the specific viruses identified, respiratory syncytial
virus was detected in 20.8% of the children. Human rhino/
enterovirus and coronavirus OC43 were detected in 16.7%
and 14.6% of the samples, respectively. Table 3 illustrates the
co-infection profile of the patients, detailing the number of
additional viruses detected along with HBoV.
In the group with no additional virus to HBoV, 72.2% were
male and 27.8% were female, while the group with additional
viruses had an equal distribution of sex (50.0% each; p= 0.131).
In these groups, chronic disease was present in 5.6% and
20.0% of the patients, respectively (p= 0.170). The patients’
laboratory parameters were also compared, and no significant
differences were found. In terms of birth characteristics, there
were no significant differences in birth type, birth week, or
birth weight. The length of hospital stay and requirement for
intensive care unit (ICU) admission did not differ significantly
between the two groups. ICU admission was required for
11.1% of the HBoV-only patients and 30.0% of those with coinfections (p= 0.302). High-flow nasal cannula (HNFC) was
used more frequently in patients with co-infection (40.0% vs.
11.1%, p= 0.029) (Table 4).
Cough was present in 77.8% and 76.7% of the patients,
respectively (p= 0.929). The two groups showed no significant
differences in the incidence of fever, respiratory distress,
diarrhea/vomiting, rash, or other symptoms. Physical
examination findings were similar between the groups.
However, retraction was more frequent in patients infected
two groups. Normal findings were reported in 27.8% of the
patients without additional viruses and in 40.0% of those with
additional viruses (p= 0.681). Table 5 compares the symptoms,
physical examination findings, and radiological findings
between patients with only HBoV and those with additional
viral infections.
Regarding oxygen supplementation, 72.2% of the
patients without additional viruses and 76.7% of patients
with additional viruses required oxygen supplementation
(p= 0.731). HNFC was used more frequently in the group with
additional viruses (40.0% vs. 11.1%). Mechanical ventilation
was only required in the group with additional viruses (6.7%).
There were no significant differences in the use of inhalers (p=
0.441) or antibiotics (p= 0.751). Finally, steroids were more
common in the group with additional viruses, although the
difference was not statistically significant (46.7% vs. 22.2%,
p= 0.090). Table 6 compares the treatment and management
strategies between the groups with and without additional
viruses.
DISCUSSION
Our study contributes to the understanding of HBoV
infections in pediatric patients, particularly in the context of
lower RTIs. We revisit, validate, and extend various aspects of
the existing literature to further enhance the comprehension of this infection. In concordance with previous findings, such
as those by Kesebir et al., our study’s demographics indicated
a marginal male predominance, with a mean age of 23.8
months among HBoV infections (8). This finding suggests a
potential sex-related disparity in susceptibility that warrants
further exploration.
The peak incidence of HBoV infections during autumn
noted in our study is consistent with studies by Calvo et al.
and Silva et al., suggesting a plausible relationship between
environmental conditions and HBoV transmission (9,10). The
seasonal pattern of HBoV infection, with a peak in autumn,
is consistent with a body of research pointing to a higher
frequency of HBoV infections during colder months (9,11). Liu
et al. observed dual peaks in the prevalence of HBoV in the
summer (from June to September) and winter (from November
to December) months. They reported a notable positive
association between the incidence of HBoV and average
temperature, in contrast to a negative relationship with
mean relative humidity. Interestingly, the mean temperature
of the previous month provided a more robust explanation
for prevalence than the temperature of the current month
(12). This pattern suggests a possible relationship between
environmental conditions and HBoV transmission, an area
that requires further exploration.
Our study found fever and cough to be the most common
symptoms of HBoV infection, consistent with numerous previous
studies, confirming the typical clinical profile of HBoV infection
(3,9,10). The prevalence of these symptoms underscores the
need for heightened diagnostic suspicion in pediatric patients
presenting with such a clinical picture. The results of our
study reaffirmed that fever and cough are the predominant
symptoms associated with HBoV infection, a finding that
corresponds with a number of previous studies, including
those conducted by Bakir et al. and Kesebir et al. (1,8). This
pattern of symptoms effectively consolidates the established
clinical profile of HBoV infection. In light of these findings, it
is evident that the prominence of these symptoms (fever and
cough) calls for an elevated level of alertness and suspicion in
the diagnostic process, particularly when dealing with pediatric
patients exhibiting such symptoms. This is crucial, as early
identification and appropriate management of HBoV infections
can significantly impact the course of the disease, especially in
this vulnerable population. However, it is noteworthy that while
fever and cough are common symptoms, the presentation of
HBoV infections can vary, and other symptoms or complications
should not be dismissed. Here, we analyzed patients with a
commonly lower RTI; however, HBoV infection may present
with diarrhea, vomiting, rash, encephalitis, or eye symptoms
(3,9,10). Furthermore, it is important to consider co-infections
that may complicate or amplify symptomatology. A key finding of our study was the prevalence of coinfections with HBoV and other respiratory viruses. This
aligns with the results of Allander et al., Foulongne et al., and
others have reported co-infections as a recurring theme in
HBoV infection (13,14). Given the frequency of co-infection,
future studies must dissect the interactions between HBoV
and other respiratory viruses to elucidate the effects of coinfection on disease trajectory. Investigating respiratory
tract illnesses can be challenging, given the wide array of
pathogens that can produce similar symptoms. Moreover,
respiratory tract samples from healthy individuals or patients
without respiratory symptoms are seldom accessible, which
complicates the study. Allender et al. addressed this problem
by comparing 258 cases of lower RTIs with a confirmed cause to
282 instances in which the cause remained unknown (13). They
primarily found HBoV in the segment of patients with lower
RTI with unresolved etiology, and this uneven distribution
indicated that HBoV is a probable pathogenic agent of lower
RTI. The three instances of co-infection involving HBoV and
another virus did not negate this conclusion. Co-infections
are often encountered in studies with lower RTI, likely because
of the high prevalence of viral infections among infants and
young children.ligning with the works of Pierangelli et al. and Calvo et al.
our study confirmed the frequent occurrence of coinfections
with HBoV and other respiratory viruses (15,16). However,
our comparative analysis revealed intriguing trends. Despite
the lack of significant disparities in demographic, laboratory,
and birth characteristics between the co-infected patients
and those with HBoV monoinfection, the co-infected group
exhibited a higher frequency of retraction and greater demand
for HNFC and mechanical ventilation, echoing the findings
of Franz et al. (17). Furthermore, we found that treatment
strategies for the co-infected group diverged, marked by
increased use of oseltamivir (only influenza) and steroids,
underlining the potential need for personalized treatment
plans for co-infected patients, an aspect underscored by Yen
et al. (18). Nevertheless, our study did not find any significant
differences in symptomatology, physical examination
findings, radiological findings, or duration of hospital stay
between the two groups. This is partially inconsistent with
the findings of Schildgen et al., who reported a more severe
clinical course in co-infected patients (19). In addition, our
findings are consistent with those of Kim et al., who reported
that co-infection with numerous viruses does not correlate
with increased disease severity in pediatric patients with
bronchiolitis (20).
This study has several limitations. Its retrospective and
cross-sectional design precludes causal inference. The limited
sample size reduces statistical power and generalizability.
Additionally, being a single-center study may introduce
referral bias. These limitations should be addressed in future
multicenter and prospective studies.
CONCLUSION
Although our findings add valuable insights to the existing
literature, some limitations must be noted. The study’s small
sample size may constrain the generalizability of the results,
and its cross-sectional nature limits our ability to infer causality.
Our results highlight the complex nature of HBoV infections
in pediatric patients and the possible role of co-infections in
shaping clinical presentations and treatment approaches.
Acknowledgments
We thank the virology and molecular diagnostics
laboratory team for their technical assistance. We also
express our sincere appreciation to Assoc. Prof. Feruza Turan
Sönmez for her valuable supervision and contribution to the
conceptualization and planning of this study.
REFERENCES
1
Bakir A, Karabulut N, Alacam S, Mese S, Somer A, Agacfidan A. Investigation of human bocavirus in pediatric patients with respiratory
tract infection. J Infect Dev Ctries 2020;14(10):1191-6. https://doi.
org/10.3855/jidc.12553
2
Silva PE, Figueiredo CA, Luchs A, de Paiva TM, Pinho MAB, Paulino RS, et
al. Human bocavirus in hospitalized children under 5 years with acute
respiratory infection, Sao Paulo, Brazil, 2010. Arch Virol 2018;163:1325-
30. https://doi.org/10.1007/s00705-017-3694-5
3
Wang K, Wang W, Yan H, Ren P, Zhang J, Shen J, et al. Correlation between bocavirus infection and humoral response, and co-infection with
other respiratory viruses in children with acute respiratory infection. J
Clin Virol 2010;47(2):148-55. https://doi.org/10.1016/j.jcv.2009.11.015
4
Liu WK, Liu Q, Chen DH, Tan WP, Cai Y, Qiu SY, et al. Epidemiology of
HBoV1 infection and relationship with meteorological conditions in
hospitalized pediatric patients with acute respiratory illness: a 7-year
study in a subtropical region. BMC Infect Dis 2018;18(1):1-8. https://doi.
org/10.1186/s12879-018-3225-3
5
Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of
respiratory tract samples. Proc Natl Acad Sci U S A 2005;102(36):12891-
6. https://doi.org/10.1073/pnas.0504666102
6
Foulongne V, Olejnik Y, Perez V, Elaerts S, Rodière M, Segondy M. Human
bocavirus in French children. Emerg Infect Dis 2006;12(8):1251. https://
doi.org/10.3201/eid1208.060213
7
Pierangeli A, Scagnolari C, Trombetti S, Grossi R, Battaglia M, Moretti
C, et al. Human bocavirus infection in hospitalized children in Italy. Influenza Other Respir Viruses 2008;2(5):175-9. https://doi.org/10.1111/
j.1750-2659.2008.00057.x
8
Calvo C, García-García ML, Pozo F, Paula G, Molinero M, Calderón A,
et al. Respiratory syncytial virus co-infections with rhinovirus and
human bocavirus in hospitalized children. Medicine (Baltimore)
2015;94(42):e1788. https://doi.org/10.1097/MD.0000000000001788
9
Franz A, Adams O, Willems R, Bonzel L, Neuhausen N, Schweizer-Krantz
S, et al. Correlation of viral load of respiratory pathogens and co-infections with disease severity in children hospitalized for lower respiratory
tract infection. J Clin Virol 2010;48(4):239-45. https://doi.org/10.1016/j.
jcv.2010.05.007
10
Yen CY, Wu WT, Chang CY, Wong YC, Lai CC, Chan YJ, et al. Viral etiologies of acute respiratory tract infections among hospitalized children-A comparison between single and multiple viral infections. J Microbiol Immunol Infect 2019;52(6):902-10. https://doi.org/10.1016/j.
jmii.2019.08.013
11
Schildgen V, van den Hoogen B, Fouchier R, Tripp RA, Alvarez R, Manoha C, et al. Human Metapneumovirus: lessons learned over the first
decade. Clin Microbiol Rev 2011;24(4):734-54. https://doi.org/10.1128/
CMR.00015-11
12
Petrarca L, Nenna R, Frassanito A, Pierangeli A, Di Mattia G, Scagnolari
C, et al. Human bocavirus in children hospitalized for acute respiratory tract infection in Rome. World J Pediatr 2020;16:293-8. https://doi.
org/10.1007/s12519-019-00324-5
13
Brand HK, de Groot R, Galama JM, Brouwer ML, Teuwen K, Hermans
PW, et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. Pediatr Pulmonol
2012;47(4):393-400. https://doi.org/10.1002/ppul.21552
14
Zaghloul MZ. Human bocavirus (HBoV) in children with respiratory
tract infection by enzyme linked immunosorbent assay (ELISA) and
qualitative polymerase chain reaction (PCR). Virol J 2011;8(1):1-5.
https://doi.org/10.1186/1743-422X-8-239
15
Bharaj P, Sullender WM, Kabra SK, Broor S. Human bocavirus infection
in children with acute respiratory tract infection in India. J Med Virol
2010;82(5):812-6. https://doi.org/10.1002/jmv.21637
16
Tabl HAEM, Emam SM, Assar EH. Human bocavirus among viral causes of pediatric respiratory tract infections at benha university hospital.
Egyptian J Med Microbiol 2012;38(1230):1-18.
17
Tan BH, Lim EAS, Seah SGK, Loo LH, Tee NW, Lin RT, et al. The incidence of
human bocavirus infection among children admitted to hospital in Singapore. J Med Virol 2009;81(1):82-9. https://doi.org/10.1002/jmv.21361
18
Naghipour M, Cuevas LE, Bakhshinejad T, Dove W, Hart CA. Human bocavirus in Iranian children with acute respiratory infections. J Med Virol
2007;79(5):539-43. https://doi.org/10.1002/jmv.20815
19
Kesebir D, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Landry ML, et
al. Human bocavirus infection in young children in the United States:
molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis 2006;194(9):1276-82. https://
doi.org/10.1086/508213
20
Calvo C, García‐García ML, Pozo F, Carballo D, Martínez‐Monteserín
E, Casas I. Infections and co-infections by respiratory human bocavirus during eight seasons in hospitalized children. J Med Virol
2016;88(12):2052-8. https://doi.org/10.1002/jmv.24562